Electrosoft today announced that the National Institute of Standards and Technology has awarded the company a follow-on contract to support the Profile Analysis and Comparison Tool (P-ACT) production tool and the validation of the Application Programming Interface (API). Under the contract, Electrosoft will continue providing NIST with project and technical support for standards and technology development leading to the adoption, measurement, and development of software testing tools. The primary goal is to improve the quality and correctness of software used in the nation’s critical infrastructures, including healthcare.

“NIST is on the forefront of developing forward-looking standards and health information technology designed to achieve industry interoperability,” said Mike Tillman, COO of Electrosoft. “We are pleased to be able to continue leveraging our extensive experience at NIST to assist in the development and transfer of technology and expertise to the industry.”

The Health IT Standards Testing is a collaborative effort to help ensure interoperability among all healthcare providers, hospitals, clinical laboratories, pharmacies, payers, and others via the meaningful use criteria. NIST supports these communities by providing standards guidance and testing tools.

This task order focuses on the development of healthcare data exchange standards and testing for industry stakeholders, seeking to contribute to testing the toolset which is used by the healthcare industry. Electrosoft will support the advancement of healthcare information standards that are complete and testable — and will provide the necessary conformance tests, tests tools, and techniques, where appropriate.

See the news here.

Ad



Not Yet a Premium Partner/Sponsor? Learn more about the OS AI Premium Corporate and Individual Plans here. Plans start at $250 annually.

How useful was this post?

Click on a star to rate it!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Leave a Reply